Evidence outlook
Approved: Crohn's Disease, Psoriatic Arthritis, Ulcerative Colitis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Competitive landscape
118 competitors in this universe: 18 direct rivals (same mechanism and indication), 2 same-class, 98 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Ustekinumab-Stba (Steqeyma): this drug | Approved | — | IL-23 p19, IL-12 p40 | ||
| Guselkumab (Tremfya) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Mirikizumab (Omvoh) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Risankizumab (Skyrizi) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Tildrakizumab (Ilumya) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Ustekinumab (Stelara) | Approved | Monoclonal antibody | IL-12 p40 | ||
| Ustekinumab-Aauz (Otulfi) | Approved | — | IL-12 p40 | ||
| Ustekinumab-Aekn (Selarsdi) | Approved | — | IL-12 p40 | ||
| Ustekinumab-Auub (Wezlana) | Approved | — | IL-12 p40 | ||
| Ustekinumab-Hmny (Starjemza) | Approved | — | IL-12 p40 | ||
| Ustekinumab-Srlf (Imuldosa) | Approved | — | IL-12 p40 | ||
| Ustekinumab-Ttwe (Pyzchiva) | Approved | — | IL-23 p19, IL-12 p40 | ||
| JNJ-78934804 | Phase 3 | Combination | IL-23 p19, TNF-alpha | ||
| Picankibart | Phase 3 | Monoclonal antibody | IL-23 p19 | ||
| MT-201 | Phase 2 | Multispecific antibody | TL1A, IL-23 p19 | ||
| SHR-1139 | Phase 2 | Monoclonal antibody | IL-23 p19, IL-36 receptor |
…and 103 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
1 further head-to-head pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.